|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 29/00 | (2018.01) |
| A61K 31/4184 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 9/14 | (2018.01) | ||
| A61P 19/02 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 31/4184 | (2013.01) | ||
| C07D 471/04 | (2013.01) | ||
| A61K2039/505 | (2013.01) | ||
| C07K 16/2887 | (2013.01) | ||
| C07K2317/24 | (2013.01) | ||
| A61K 39/39558 | (2013.01) | ||
| A61K 31/496 | (2013.01) | ||
| A61K 31/675 | (2013.01) | ||
| A61K 31/704 | (2013.01) | ||
| A61K 31/475 | (2013.01) | ||
| A61K 31/573 | (2013.01) |
| (11) | Number of the document | 3672591 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19845466.2 |
| Date of filing the European patent application | 2019-07-22 | |
| (97) | Date of publication of the European application | 2020-07-01 |
| (45) | Date of publication and mention of the grant of the patent | 2024-02-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/CN2019/097028 |
| Date | 2019-07-22 |
| (87) | Number | WO 2020/024826 |
| Date | 2020-02-06 |
| (30) | Number | Date | Country code |
| 201810867252 | 2018-07-31 | CN |
| (72) |
YANG, Dajun , CN
ZHAI, Yifan , CN
WANG, Guangfeng , CN
|
| (73) |
Ascentage Pharma (Suzhou) Co., Ltd. ,
Unit 701, Building B7, 218 Xinghu Street
Suzhou Industrial Park, Suzhou, Jiangsu 215000,
CN
|
| (54) | SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP |
| SYNERGISTIC ANTITUMOR EFFECT OF BCL-2 INHIBITOR COMBINED WITH RITUXIMAB AND/OR BENDAMUSTINE OR BCL-2 INHIBITOR COMBINED WITH CHOP |